

1 **Orthopedic Non-Spinal Metallic Bone**
2 **Screws and Washers – Performance**
3 **Criteria for Safety and Performance**
4 **Based Pathway**

7 **Draft Guidance for Industry and**
8 **Food and Drug Administration Staff**

9 ***DRAFT GUIDANCE***

10 **This draft guidance document is being distributed for comment purposes**
11 **only.**

12 **Document issued on September 20, 2019.**

13
14
15
16
17 You should submit comments and suggestions regarding this draft document within 90 days of
18 publication in the *Federal Register* of the notice announcing the availability of the draft
19 guidance. Submit electronic comments to <https://www.regulations.gov>. Submit written
20 comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630
21 Fishers Lane, rm. 1061, Rockville, MD 20852. Identify all comments with the docket number
22 listed in the notice of availability that publishes in the *Federal Register*.

23
24 For questions about this document, contact the DHT6C: Division of Stereotaxic, Trauma and
25 Restorative Devices at 301-796-5650 or Christopher Ferreira at
26 Christopher.Ferreira@fda.hhs.gov.



31 U.S. Department of Health and Human Services
32 Food and Drug Administration
33 Center for Devices and Radiological Health
34

Preface

36

37

Additional Copies

39

40 Additional copies are available from the Internet. You may also send an e-mail request to
41 CDRH-Guidance@fda.hhs.gov to receive a copy of the guidance. Please include the document
42 number 19009 and complete title of the guidance in the request.

43

44

DRAFT

Orthopedic Non-Spinal Metallic Bone Screws and Washers – Performance Criteria for Safety and Performance Based Pathway

Draft Guidance for Industry and Food and Drug Administration Staff

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.

I. Introduction

This draft guidance provides performance criteria for non-spinal metallic bone screws and their associated washers in support of the [Safety and Performance Based Pathway](#).¹ Under this framework, submitters planning to submit a 510(k) using the Safety and Performance Based Pathway for non-spinal metallic bone screws and washers will have the option to use the performance criteria proposed in this draft guidance to support substantial equivalence, rather than a direct comparison of the performance of the subject device to that of a predicate device.

For the current edition of the FDA-recognized standard(s) referenced in this document, see the [FDA Recognized Consensus Standards Database](#).² For more information regarding use of consensus standards in regulatory submissions, please refer to the FDA guidance titled [Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices](#).³

¹ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-and-performance-based-pathway>

² Available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm>

³ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices>

Contains Nonbinding Recommendations

Draft – Not for Implementation

75 FDA's guidance documents, including this draft guidance, do not establish legally enforceable
76 responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should
77 be viewed only as recommendations, unless specific regulatory or statutory requirements are
78 cited. The use of the word *should* in Agency guidance means that something is suggested or
79 recommended, but not required.
80

81 **II. Scope/Device Description**

82 The devices that are the subject of this guidance are Class II non-spinal metallic bone screws
83 and washers regulated under 21 CFR 888.3040, product codes HWC (screw, fixation, bone) and
84 HTN (washer, bolt nut), respectively.
85

86 **Intended Use/Indications for Use:** The bone screws that fall within the scope of this guidance
87 document are intended for orthopedic non-spinal fracture fixation, osteotomy, or small joint
88 fusion or arthrodesis. The washers that fall within the scope of this guidance document are
89 intended for use with bone screws only to aid in load distribution at the screw head/bone
90 interface. Bone screws or washers that are intended for mandibular, maxillofacial, cranial and
91 orbital fracture fixation or for use in the spine are outside the scope of this guidance document.
92 Devices intended for use with suture or chord components (e.g., bone anchors, syndesmosis
93 tight ropes) as part of an implant system are also outside the scope of this guidance document.
94

95 **Device Design Characteristics:** Bone screws of varying designs (e.g., cancellous screws,
96 cortical screws, cannulated screws, fully threaded screws, partially threaded screws) are
97 included within the scope of this guidance. Devices that fall within the scope of this guidance
98 document consist of bone screws and washers manufactured solely from one of the following
99 materials in conformance with the associated FDA-recognized consensus standard:

- 100 • American Society for Testing and Materials (ASTM) F136 *Standard Specification for*
101 *Wrought Titanium-6 Aluminum-4 Vanadium ELI (Extra Low Interstitial) Alloy for*
102 *Surgical Implant Applications (UNS R56401)*
- 103 • ASTM F1295 *Standard Specification for Wrought Titanium-6 Aluminum-7Niobium*
104 *Alloy for Surgical Implant Applications (UNS R56700)*
- 105 • ASTM F67 *Standard Specification for Unalloyed Titanium, for Surgical Implant*
106 *Applications (UNS R50250, UNS R50400, UNS R50550, UNS R50700)*
- 107 • ASTM F138 *Standard Specification for Wrought 18 Chromium-14 Nickel-2.5*
108 *Molybdenum Stainless Steel Bar and Wire for Surgical Implants (UNS S31673)*
- 109 • ASTM F1537 *Standard Specification for Wrought Cobalt-28-Chromium-6-Molybdenum*
110 *Alloys for Surgical Implants (UNS R31537, UNS R31538, and UNS R31539)*
111

112 Compatible drill bits for all screw diameters and types should be no larger than the core
113 diameter of their compatible screws, and pilot hole diameters should be specified in the
114 instructions for use for each screw size. Washers should be at least 0.5mm thick and be
115 constructed of the same material as the compatible screw. Additionally, the inner diameter of a
116 washer should be larger than the compatible screw's thread diameter, and the inner diameter of
117 the washer should be less than the diameter of the screw head.

Contains Nonbinding Recommendations

Draft – Not for Implementation

118

119 Implants with the following features are not eligible for the Safety and Performance Based
120 Pathway via this guidance:

- 121 • Combination products
- 122 • Resorbable devices
- 123 • Additively manufactured devices
- 124 • Devices which utilize surgical techniques or associated instruments outside the standard
125 of care
- 126 • Devices with complex geometries or modularities (e.g., segmented, fenestrated)
- 127 • Devices with other unique technological characteristics (e.g., unique screw thread)

128

129 Where FDA determines that additional data are necessary to make these determinations, the
130 Agency may, on a case-by-case basis, review that data before determining whether or not the
131 device is appropriate for the Safety and Performance Based Pathway. In situations, where you
132 determine that additional testing outside of those identified in this guidance are necessary to
133 make a determination regarding eligibility into the Safety and Performance Based Pathway, we
134 would encourage sponsors to submit a Pre-Submission⁴ to engage in discussion with FDA prior
135 to submission of the 510(k).

136

137 **III. Testing Performance Criteria**

138 If your device is appropriate for submission through the Safety and Performance Based Pathway,
139 and you choose to use that option, you do not need to provide direct comparison testing against a
140 legally marketed predicate to demonstrate substantially equivalent performance characteristics.

141 To ensure that the performance criteria outlined in this guidance remain contemporary and take
142 into account relevant data from recent clearances, FDA recommends that you provide a results
143 summary for all tests evaluated in addition to the other submission information (e.g., Declaration
144 of Conformity (DoC)) identified for each test or evaluation below. Unless otherwise identified in
145 the submission information sections below, test information such as results summary, test
146 protocols, or complete test reports should be submitted as part of the 510(k) as described in
147 FDA's guidance [Safety and Performance Based Pathway](#).⁵ For additional information regarding
148 the submission of non-clinical bench testing information, please see FDA's guidance
149 [Recommended Content and Format of Non-Clinical Bench Performance Testing Information in
150 Premarket Submissions](#).⁶

151

152

153

154

⁴ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program>

⁵ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-and-performance-based-pathway>

⁶ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-content-and-format-non-clinical-bench-performance-testing-information-premarket>

Contains Nonbinding Recommendations

Draft – Not for Implementation

155 **Mechanical Bench Testing**

156
157 The following mechanical tests should be performed in conformance with the FDA currently-
158 recognized version of ASTM F543 *Standard Specification and Test Methods for Metallic*
159 *Medical Bone Screw*. We recommend that you perform all testing on screw designs that
160 represent worst-case (e.g., most likely to loosen or fail) final design versions. You should also
161 provide a rationale identifying how you identified the worst-case design. Additionally, axial
162 pullout strength should be evaluated using an engineering analysis method described below.
163 Acceptance criteria are listed below for each test.⁷

164
165 For each mechanical test below, you should provide a report as specified in the relevant reporting
166 sections of ASTM F543, in addition to a Declaration of Conformity (DoC) to the consensus
167 standard. Any protocol deviations should be thoroughly described and justified; however, note
168 that certain protocol deviations may invalidate comparison to the performance criteria listed
169 below, resulting in the need for submission of a Traditional, Special, or Abbreviated 510(k), as
170 appropriate.

- 171
172 1. **Test name:** Torsional Strength
173 **Methodology:** ASTM F543 *Standard Specification and Test Methods for Metallic*
174 *Medical Bone Screws*
175 **Performance Criteria:** The worst-case bone screw should be selected for mechanical
176 testing:
177

Nominal Major Diameter (mm)	Torsional Yield Strength (Nm)
1.5	0.16
2	0.35
2.5	0.60
2.7	1.0
3	1.0
3.5	2.1
4	2.3
4.5	3.5
5	4.3
5.5	5.9
6	9.5

178

⁷ It should be noted that although ASTM F543 is FDA-recognized in full, FDA believes that for the purposes of the safety and performance based pathway, the testing, methods and criteria identified in this section on mechanical bench testing represent the least burdensome approach to demonstrating substantial equivalence for this pathway, although alternative or additional methods or acceptance criteria are identified in the recognized consensus standard for some tests. The supplementary information sheet for ASTM F543 will be revised to reflect this information upon finalization of this guidance.

Contains Nonbinding Recommendations

Draft – Not for Implementation

179 Note that the acceptance criterion is based on the torsional yield strength, which is a more
180 conservative indicator of screw failure strength than the maximum torque strength
181 identified in ASTM F543.

182
183 **Performance Criteria Source:** Criteria are based on aggregated mechanical testing data
184 submitted to FDA in 510(k) submissions for orthopedic bone screws previously found to
185 be substantially equivalent. It should be noted that the values in the table above were
186 rounded to be the most inclusive and accurate based on the final data.

187 **Additional Considerations:** As specified in ASTM F543, a minimum of five samples
188 should be tested. In addition, analysis of the data available to FDA on existing devices
189 has shown that five samples should be adequate based on the mean torsional yield
190 strength testing results compared to the criteria for each nominal diameter. To be
191 considered a successful result, either: (1) All samples should meet or exceed the
192 acceptance criteria listed above, (2) the average of all samples should meet or exceed the
193 criteria above and the standard deviation should be $\leq 10\%$ of the calculated average, or
194 (3) the criteria derived from ASTM E122 *Calculating Sample Size to Estimate, With*
195 *Specified Precision, the Average for a Characteristic of a Lot or Process* should be met,
196 as suggested in ASTM F543. The table value selected for the acceptance criterion should
197 be based on the worst-case screw nominal major diameter. If the nominal major diameter
198 is not listed in this table, the next highest diameter torsional strength value should be used
199 as the acceptance criterion.

200 **Submission Information:** Results summary and DoC

201

202 2. **Test name:** Driving Torque

203 **Methodology:** ASTM F543 *Standard Specification and Test Methods for Metallic*
204 *Medical Bone Screws*

205 **Performance Criteria:** The worst-case bone screw used in torsional strength testing
206 should be tested in insertion and removal testing. The maximum torque recorded in
207 insertion and removal testing (recorded in Newton-meters) should be 50% of or less
208 torque than the torsional yield strength for insertion into a minimum of 20 pcf bone foam.
209 Additionally, visual inspection should be performed on screws following their removal,
210 and images of the final test samples should be provided to demonstrate that the screw
211 threads adequately resist damage, such as disassociation of the screw thread from the
212 screw body.

213 **Performance Criteria Source:** Criteria are based on aggregated mechanical testing data
214 submitted to FDA in 510(k) submissions for orthopedic bone screws previously found to
215 be substantially equivalent.

216 **Additional Considerations:** In order to be considered a successful result, all samples
217 should meet or exceed the acceptance criteria listed above.

218 **Submission Information:** Results summary and DoC

219

220 3. **Test name:** Axial Pullout Strength

221 **Methodology:** For all screw diameters and types, the pilot hole diameter should be no
222 larger than the minor diameter of the screw in order to use the engineering analysis
223 below. Note than an engineering analysis is recommended in lieu of bench testing

Contains Nonbinding Recommendations

Draft – Not for Implementation

224 described in ASTM F543 to assess axial pullout strength when demonstrating substantial
225 equivalence using the safety and performance pathway due to significant variations in test
226 outcomes resulting from small differences in the test blocks used, even when the blocks
227 conform to the specifications in ASTM F1839 *Standard Specification for Rigid*
228 *Polyurethane Foam for Use as a Standard Material for Testing Orthopaedic Devices and*
229 *Instruments.*

230

231 For all screws, extract the relevant dimensions below (i.e. screw major diameter, screw
232 minor diameter, screw pitch, and axial thread length). These dimensions will be used to
233 calculate theoretical pullout strengths for the smallest axial thread lengthened screws in
234 the device system using the following equation (Chapman et al., 1996)⁸:

235

$$F_s = S * A = \{S * L * \pi * D_{major} * TSF\}$$

237

238 F_s = predicted shear failure force (N)

239 S = material ultimate shear stress (MPa)

240 A = thread shear area (mm²)

241 L = length of thread engagement in material (mm)

242 D_{major} = major diameter (mm)

243 TSF = Thread Shape Factor (dimensionless) = $(0.5 + 0.57735 d/p)$

244 d = thread depth (mm) = $(D_{major} - D_{minor})/2$

245 D_{minor} = minor (root) diameter (mm)

246 p = thread pitch (mm)

247

248 Using a material ultimate shear stress value of 3.395 MPa (representative of 20 pcf bone
249 foam), the resulting theoretical pullout strength value obtained for the device should be
250 equivalent or greater to the following values depending on the nominal major diameter of
251 the worst-case screws. A justification should be provided to support why the evaluated
252 screws selected are worst case. Axial pullout performance is heavily influenced by
253 amount of interface. Factors such as decreasing outer diameter and decreasing axial
254 thread length may help identify the worst case.

255

256 Dimensions used for calculations should be clearly listed for each theoretical outcome.

257 Dimensional values used in this calculation should be consistent with the values listed on
258 the screw engineering drawings.

259

⁸ Chapman, J. R. (1996). Factors Affecting the Pullout Strength of Cancellous Bone Screws. *Journal of Biomechanical Engineering*, 118(3), 391. doi:10.1115/1.2796022

Contains Nonbinding Recommendations

Draft – Not for Implementation

260
261

Performance Criteria:

Nominal Major Diameter (mm)	Theoretical Pullout Strength (N)
1.5	45.6
2	50.5
2.5	55.5
2.7	79.5
3	92.0
3.5	112.5
4	148.4
4.5	152.3
5	230.7
5.5	336.0
6	468.6
6.5	503.5

262
263
264
265
266
267
268
269

Performance Criteria Source: Criteria are based on aggregated mechanical testing data and device description information submitted to FDA in 510(k) submissions for orthopedic bone screws previously found to be substantially equivalent.

Submission Information: Results summary and engineering analysis

Sterilization (devices labeled as sterile) and Reprocessing (end-user sterilized) Validation

270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287

4. **Test name:** Sterilization (devices labeled as sterile) and Reprocessing (end-user sterilized)

Methodology: FDA currently-recognized versions of the following consensus standards (as applicable):

- International Organization for Standardization (ISO) 17665-1 *Sterilization of health care products – Moist heat – Part 1: Requirements for the development, validation, and routine control of a sterilization process for medical devices*
- ISO 11135-1 *Sterilization of health care products – Ethylene oxide – Part 1: Requirements for development, validation, and routine control of a sterilization process for medical devices*
- ISO 11137-1 *Sterilization of health care products – Radiation – Part 1: Requirements for development, validation, and routine control of a sterilization process for medical devices*
- ISO 11607-1 *Packaging for terminally sterilized medical devices – Part 1: Requirements for materials, sterile barrier systems and packaging systems*
- ISO 11607-2 *Packaging for terminally sterilized medical devices – Part 2: Validation requirements for forming, sealing and assembly processes*

Contains Nonbinding Recommendations

Draft – Not for Implementation

288 **Performance Criteria:** Validation testing should demonstrate the cleanliness and
289 sterility of, or the ability to clean and sterilize to a sterility assurance level of 10^{-6} , the
290 device and device-specific instruments. You should provide a description of the
291 packaging (sterile barrier system) and how it will maintain the device’s sterility, and a
292 description of the package test methods, but not package test data.

293 **Performance Criteria Source:** FDA’s guidance:

- 294 • [Submission and Review of Sterility Information in Premarket Notification](#)
295 [\(510\(k\)\) Submissions for Devices Labeled as Sterile](#)⁹
- 296 • [Reprocessing Medical Devices in Health Care Settings: Validation Methods and](#)
297 [Labeling](#)¹⁰

298 **Submission Information:** If using an Established Category A sterilization method, you
299 should provide the information described in Section V.A. of the FDA guidance
300 [Submission and Review of Sterility Information in Premarket Notification \(510\(k\)\)](#)
301 [Submissions for Devices Labeled as Sterile](#); the validation data itself is not needed to
302 demonstrate substantial equivalence.

303 **Biocompatibility Evaluation:**

304 To identify the biocompatibility endpoints to include as part of your biocompatibility evaluation
305 you should use Attachment A of CDRH’s guidance [Use of International Standard ISO 10993-1,](#)
306 [Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk](#)
307 [management process](#),¹¹ referred to in the rest of this document as the CDRH Biocompatibility
308 Guidance for brevity. FDA considers the devices covered by this guidance to be categorized as
309 Implanted Devices in contact with tissue/bone with a “permanent” contact duration of > 30 days
310 and you should assess the endpoints below per Attachment A of the CDRH Biocompatibility
311 Guidance.

- 314 • Cytotoxicity
- 315 • Sensitization
- 316 • Irritation or Intracutaneous Reactivity
- 317 • Acute Systemic Toxicity
- 318 • Material-Mediated Pyrogenicity
- 319 • Sub-acute/Sub-chronic Toxicity
- 320 • Genotoxicity
- 321 • Implantation
- 322 • Chronic Toxicity
- 323 • Carcinogenicity

324

⁹ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-and-review-sterility-information-premarket-notification-510k-submissions-devices-labeled>

¹⁰ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reprocessing-medical-devices-health-care-settings-validation-methods-and-labeling>

¹¹ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-international-standard-iso-10993-1-biological-evaluation-medical-devices-part-1-evaluation-and>

Contains Nonbinding Recommendations

Draft – Not for Implementation

325 **Rationale in Lieu of Testing:** If the subject device is manufactured from the identical raw
326 materials using identical manufacturing processes as a predicate device with the same type and
327 duration of tissue contact, and any changes in geometry are not expected to impact the biological
328 response, this is typically sufficient to establish substantially equivalent biocompatibility, if
329 documentation such as that outlined in Attachment F of the CDRH Biocompatibility Guidance is
330 also provided.

331
332 **Testing:** In rare cases, if you determined that testing is needed to address some or all of the
333 identified biocompatibility endpoints, FDA recommends that complete test reports be provided
334 for all tests performed unless a declaration of conformity without supplemental information can
335 be appropriately provided, per Attachment E of the CDRH Biocompatibility Guidance. Any test-
336 specific positive, negative, and/or reagent controls should perform as expected, and protocol
337 deviations should be thoroughly described and justified; however, note that certain protocol
338 deviations may invalidate comparison to the performance criteria listed below and require
339 submission of a Traditional, Special, or Abbreviated 510(k).

- 340
341 5. **Test name:** Biocompatibility endpoints (identified from CDRH Biocompatibility
342 Guidance)
343 **Methodology:** FDA currently-recognized versions of biocompatibility consensus
344 standards
345 **Performance Criteria:** All direct or indirect tissue contacting components of the device
346 and device-specific instruments should be determined to have an acceptable biological
347 response.
348 **Performance Criteria Source:** The CDRH Biocompatibility Guidance
349 **Additional Considerations:** For any biocompatibility test samples with an adverse
350 biological response, the biocompatibility evaluation should explain why the level of
351 toxicity seen is acceptable. Some comparison testing against a legally marketed predicate
352 may be necessary (and is considered acceptable under the Safety and Performance Based
353 Pathway) to support such a rationale as explained in the CDRH Biocompatibility
354 Guidance. For standard biocompatibility test methods that include comparison device
355 control samples, the legally marketed comparison device control samples should perform
356 as expected, as specified above for the subject device samples.
357 **Submission Information:** Refer to CDRH Biocompatibility Guidance